SSY Group (HKG:2005) said it has received drug production and registration approval from China's National Medical Products Administration for its 4mg Tolterodine Tartrate sustained-release capsules, according to a Friday Hong Kong bourse filing.
The product, classified as a type 4 chemical drug and deemed to have passed consistency evaluation, is used for managing overactive bladder, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments